Autologous Chondrocyte Implantation (ACI) and Matrix-induced Autologous Chondrocyte Implant (MACI) Medical Guideline
Customize your policy alerts
Sign up for WPS Health Insurance Policy PUM 250-0032-1812 alerts
Get alerted when Policy PUM 250-0032-1812 changes without checking for updates manually.
Monitor payer policy activity
This guideline governs medical necessity and coverage criteria for ACI and MACI to repair knee articular cartilage defects for WPS members, subject to the applicable benefit plan, exclusions, authorization requirements, and state or federal requirements.
No material clinical or coverage changes in this revision.
Medical Necessity and Coverage Criteria
Medically necessary ACI or MACI
Covered as medically necessary when the individual has provided informed consent, agreed to postoperative restrictions and rehabilitation, and all of the following criteria are met.
All medical-necessity criteria
- Patient factors: The individual is 15 through 55 years old and has a body mass index (BMI) of 35 or less.Age 15-55 years; BMI <=35
For individuals younger than 18 years, documentation of growth-plate closure is required.
- Symptoms and functional impact: The individual experiences knee catching or locking, or pain that affects the ability to ambulate or complete activities of daily living.
- Conservative treatment: The individual has completed a two-month trial of medication management.Medication-management trial: 2 months
- Prior surgical treatment: Other surgical interventions have been tried and failed or are contraindicated.
Examples include osteochondral autograft or allograft, abrasion arthroplasty, microfracture, and drilling.
- Defect location and depth: There is a local articular cartilage defect caused by acute or repetitive trauma, extending down to but not through the subchondral bone, on a load-bearing surface of the patella, trochlea, or lateral or medial femoral condyle.Does not extend through the subchondral bone
- Defect size: The solitary cartilage defect does not exceed the specified maximum dimensions.Length <=6.0 cm; depth <=7 mm; area <=10 cm²
- Imaging demonstrates an intact meniscus and no joint-space narrowing.
- Alignment and stability: The knee is aligned and stable with normal weight distribution within the joint, or a procedure to ensure alignment, stability, and normal weight distribution is planned in combination with or before chondrocyte implantation.
- Arthritis and replacement status: There is no arthritis of the knee on imaging, the procedure is not being performed as treatment for degenerative arthritis, and the individual is not a candidate for total knee replacement.
Bone grafting for subchondral bone loss
A qualifying adjunct may be medically necessary when all ACI or MACI criteria are met.
The bone grafting is performed at the time of ACI or MACI implantation.
Experimental, investigational, and unproven uses
The following uses are not covered as medically necessary under this guideline and are considered experimental, investigational, and unproven to affect health outcomes.
Any excluded circumstance or treatment
Excluded clinical circumstances
- Presence of an osteochondritis dissecans (OCD) lesion.
- History of total meniscectomy.
- Malignancy is present in the area of cartilage biopsy or implantation.
- Osteoarthritis, inflammatory arthritis, or inflammatory joint disease is present.
- The individual is younger than 15 years or older than 55 years.Age <15 or >55 years
- The procedure is performed on a joint other than the knee.
- The individual has an uncorrected congenital blood coagulation disorder.
- The individual has undergone prior knee surgery within the past six months, excluding cartilage biopsy or harvest and procedures to prepare the knee for autologous chondrocyte implantation.Prior knee surgery within 6 months
- The procedure is the initial cartilage-preserving procedure on the knee, with no prior microfracture, drilling, abrasion, or osteochondral allograft or autograft.
Excluded combined procedures and adjunctive treatments
- Meniscal allograft.
- Osteochondral autograft transfer system (OATS).
- Combined autologous and allograft chondrocyte implantation.
- Meniscus reconstruction.
- Bone marrow aspirate concentrate (BMAC) injection or treatment.
- Microfragmented adipose tissue (MFAT) injection or treatment, including Lipogems®.
- Stem cell therapy or stem cell injections.
- Platelet-rich plasma (PRP) injection or treatment.
- Platelet lysate (PL).
- Viscosupplementation or hyaluronic acid injections, including Orthovisc® or Synvisc®.
- Juvenile cartilage allograft tissue implantation, including DeNovo NT® or DeNovo ET®.
- Cryopreserved viable osteochondral allograft product, including Cartiform®.
- Peripheral nerve block or ablation.
- Genicular nerve injections or genicular nerve radiofrequency ablation.
- iovera® System.
- Coolief® Cooled RF (radiofrequency).
- Cryotherapy.
- Subchondroplasty or subchondral calcium phosphate injections.
ACI or MACI is experimental, investigational, and unproven when performed for osteochondritis dissecans (OCD) lesions, after a history of total meniscectomy, or when malignancy is present in the cartilage biopsy or implantation area. It is also not covered as medically necessary for osteoarthritis, inflammatory arthritis or inflammatory joint disease; for individuals younger than 15 years or older than 55 years; for treatment of a joint other than the knee; or for an individual with an uncorrected congenital blood-coagulation disorder.
This determination also applies when knee surgery was performed within the preceding 6 months, except for cartilage biopsy or harvest and procedures performed to prepare the knee for ACI. ACI or MACI is likewise experimental, investigational, and unproven when used as the initial cartilage-preserving knee procedure without prior microfracture, drilling, abrasion, or osteochondral allograft/autograft treatment.
Combined ACI or MACI procedures and adjunctive treatments are experimental, investigational, and unproven. Excluded combinations include ACI with a meniscal allograft, osteochondral autograft transfer system (OATS), allograft chondrocytes, or meniscus reconstruction. Excluded adjunctive treatments include bone marrow aspirate concentrate (BMAC), microfragmented adipose tissue (MFAT), stem-cell therapy or injections, platelet-rich plasma (PRP), platelet lysate, viscosupplementation or hyaluronic acid, juvenile cartilage allograft tissue, and cryopreserved viable osteochondral allograft products.
The exclusion also includes peripheral nerve block or ablation, genicular nerve injections or radiofrequency ablation, iovera, Coolief cooled radiofrequency treatment, cryotherapy, and subchondroplasty or subchondral calcium phosphate injections.
When the diagnosis is included in the indications for coverage but the required coverage criteria are not met, ACI or MACI is considered not medically necessary. This determination applies even when the underlying diagnosis is otherwise eligible for consideration under the guideline.
Requirements for Coverage and Submission
Verify Plan Requirements
Before submitting ACI/MACI, review the member’s contract and endorsements for exclusions, prior authorization requirements, and benefit limitations. Verify eligibility, benefits, network status, and any plan-specific requirements with the customer service number on the member ID card.
- Check applicable exclusions and limitations.
- Confirm whether prior authorization is required.
- Verify benefit and network status before rendering services.
Conservative and Prior Treatment Requirements
Coverage requires a documented two-month trial of medication management and a history showing that other surgical interventions have been tried and failed or are contraindicated.
- Document prior or contraindicated osteochondral autograft/allograft, abrasion arthroplasty, microfracture, or drilling procedures.
- ACI/MACI is not covered as the initial cartilage-preserving procedure when no prior microfracture, drilling, abrasion, or osteochondral allograft/autograft has been performed.
- A knee surgery within the prior six months is excluded, except for cartilage biopsy/harvest or a procedure performed to prepare the knee for ACI/MACI.
Standard Written Order Required
Use a Standard Written Order (SWO) prescribed by a qualified healthcare provider concerning the member’s diagnosis and the requested service.
- Ensure the order is completed by a qualified healthcare provider.
- The order should identify the member’s diagnosis and the requested ACI/MACI service.
Medical Records Required
Submit medical records supporting medical necessity, including relevant office visit notes and documentation of continued need or use when applicable.
- Include records supporting the diagnosis, symptoms, examination, imaging, prior treatment, and planned procedure.
- Provide continued-need or use documentation when applicable.
Clinical Criteria Support
The record must support informed consent, agreement to postoperative restrictions and rehabilitation, and every applicable coverage criterion for knee cartilage repair.
- Document age 15–55 years and BMI of 35 or less; for individuals younger than 18, document closure of the growth plate.
- Document knee catching/locking or pain that limits ambulation or activities of daily living.
- Document a local articular cartilage defect from acute or repetitive trauma on a load-bearing surface of the patella, trochlea, or medial/lateral femoral condyle, extending to but not through the subchondral bone.
- Document that the solitary defect does not exceed 6.0 cm in length, 7 mm in depth, or 10 cm² in area.
- Provide imaging showing an intact meniscus, no joint-space narrowing, and no knee arthritis; the procedure must not treat degenerative arthritis.
- Document knee alignment and stability with normal weight distribution, or a planned concurrent or prior procedure to correct these issues.
- Document that the individual is not a candidate for total knee replacement.
- Addressing 6–8 mm of subchondral bone loss with bone grafting at implantation (sandwich technique) is medically necessary only when the ACI/MACI criteria are met.
Coding Documentation
Submit correct coding for the item or service and ensure all applicable coding guidelines are satisfied.
- Validate the diagnosis, procedure, and service codes before submission.
- Correct coding does not replace medical-necessity, benefit, or authorization requirements.
Unlisted Indication
If ACI/MACI is used for a condition or diagnosis not listed in the Indications of Coverage, it is considered experimental, investigational, and unproven to affect health outcomes.
- Unlisted indications are not covered as medically necessary under this guideline.
Criteria Not Met
When the condition or diagnosis is listed in the Indications of Coverage but the applicable criteria are not met, ACI/MACI is considered not medically necessary.
- Document each required criterion before requesting authorization or submitting the claim.
Excluded Clinical Circumstances
ACI/MACI is experimental, investigational, and unproven in the following clinical circumstances.
- Osteochondritis dissecans (OCD) lesions.
- History of total meniscectomy.
- Malignancy at the cartilage biopsy or implantation site.
- Osteoarthritis, inflammatory arthritis, or inflammatory joint disease.
- Individual younger than 15 or older than 55 years; treatment of any joint other than the knee.
- Uncorrected congenital blood coagulation disorder.
- Prior knee surgery within six months, except cartilage biopsy/harvest or preparation of the knee for ACI/MACI.
- Initial cartilage-preserving knee procedure without prior microfracture, drilling, abrasion, or osteochondral allograft/autograft.
Excluded Combinations and Adjuncts
The following combinations and adjunctive treatments are experimental, investigational, and unproven to affect health outcomes when associated with ACI/MACI.
- Combined ACI and meniscal allograft; combined ACI and OATS; combined autologous and allograft chondrocyte implantation; or combined meniscus reconstruction and ACI.
- Bone marrow aspirate concentrate (BMAC), microfragmented adipose tissue (MFAT, including Lipogems), or stem cell therapy/injections.
- Platelet-rich plasma (PRP), platelet lysate (PL), or viscosupplementation/hyaluronic acid injections, including Orthovisc and Synvisc.
- Juvenile cartilage allograft tissue implantation, including DeNovo NT or DeNovo ET, or cryopreserved viable osteochondral allograft products, including Cartiform.
- Peripheral nerve block or ablation; genicular nerve injections or genicular nerve radiofrequency ablation; iovera; or Coolief cooled radiofrequency.
- Cryotherapy, subchondroplasty, or subchondral calcium phosphate injections.
Benefit-Plan and Legal Conditions
Coverage remains subject to the applicable benefit plan, authorization requirements, exclusions, limitations, and state and federal law. Medical guidelines are informational and do not constitute plan authorization, an explanation of benefits, medical advice, or a guarantee of payment.
- Benefit plans vary and may not cover every service listed in the guideline; plan terms and specific exclusions control.
- State mandates, laws, or benchmarks supersede this guideline where applicable.
- Coverage is subject to medical necessity; services considered experimental, investigational, or unproven are not medically necessary under the clinical guidelines and will not be covered.
- Use the most current medical references and specialty-society guidelines, such as MCG or NCCN, together with the independent professional judgment of a qualified healthcare provider.
- Some plans administered by the organization may not use Medical Affairs guidelines in all coverage determinations.
Procedure Background
Autologous chondrocyte implantation (ACI) uses the individual's own cartilage cells to repair a damaged articular cartilage surface. The procedure generally begins with an arthroscopic cartilage biopsy, followed by laboratory expansion of the chondrocytes. The expanded cells are then implanted into the cartilage defect.
Matrix-induced autologous chondrocyte implantation (MACI) uses autologous cultured chondrocytes prepared on a porcine collagen membrane or scaffold. The cell-containing membrane or scaffold is trimmed to match the defect and implanted to support cartilage healing.
Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.